Document is current
Any future updates will be listed below
-
Authors
Hamidzada, Homaira https://orcid.org/0000-0003-0151-9608
Pascual-Gil, Simon
Wu, Qinghua
Kent, Gregory M.
Massé, Stéphane
Kantores, Crystal
Kuzmanov, Uros https://orcid.org/0000-0002-3502-6986
Gomez-Garcia, M. Juliana
Rafatian, Naimeh
Gorman, Renée A. https://orcid.org/0009-0006-9580-9807
Wauchop, Marianne
Chen, Wenliang
Landau, Shira
Subha, Tasnia
Atkins, Michael H. https://orcid.org/0000-0002-4905-7943
Zhao, Yimu
Beroncal, Erika
Fernandes, Ian
Nanthakumar, Jared
Vohra, Shabana
Wang, Erika Y.
Valdman Sadikov, Tamilla
Razani, Babak https://orcid.org/0000-0002-7172-9240
McGaha, Tracy L.
Andreazza, Ana C. https://orcid.org/0000-0002-4323-7273
Gramolini, Anthony https://orcid.org/0000-0003-1109-2070
Backx, Peter H.
Nanthakumar, Kumaraswamy
Laflamme, Michael A.
Keller, Gordon
Radisic, Milica https://orcid.org/0000-0003-1249-4135
Epelman, Slava https://orcid.org/0000-0003-3400-4475
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research
Stem Cell Network
- License Information
-
More Information
Article History
Received: 30 December 2022
Accepted: 4 April 2024
First Online: 7 May 2024
Competing interests
: M.R., Y.Z. and Q.H. are inventors on patents related to the Biowire II cardiac tissue cultivation and maturation protocols that are used as a main experimental system in this manuscript (all figures). These patents and applications cover platform fabrication, cell seeding and tissue cultivation (patent 10,034,738; patent 10,254,274; patent 11,913,940; application 17,520,303 filed on 5 November 2021; application 17798047, publication date 9 March 2023; application 17520303, publication date 12 May 2022; application 17798047, publication date 9 March 2023; and application 17520303, publication date 12 May 2022). Patents 10,254,274 and 11,913,940 are licensed to Valo Health. M.R. and Y.Z. receive royalty payments and annual fees for licensing of these inventions. M.R. and Y.Z. are also eligible for milestone payments from Valo Health related to successful discovery and translation of molecules using the Biowire II platform. All other authors declare no competing interests.
